The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.
Ignite the Spark of Joy & Discovery
A Roshi (i.e., master) apparently said that in Zen, “there is nothing to believe and everything to discover.” Interestingly enough, I have never been able to confirm who actually said that, which makes this saying about belief and discovery particularly apt. Regardless, I think about those words at least twice a day when I am…
In Memoriam: The Far-Reaching Legacy of Naomi Rothfield, MD, MACR
A tribute to the life and distinguished career of Naomi Rothfield, MD, MACR.
In Memoriam: Rodanthi Kitridou, a Titan of Rheumatology
Dr. Rodanthi Kitridou is fondly remembered by a mentee as a trailblazer and role model.
Case Report: Giant Cell Arteritis-Related Stroke
Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…
Pegloticase Plus Methotrexate Effective for Uncontrolled Gout
The 12-month results of the MIRROR study show pegloticase co-administered with methotrexate is beneficial for patients with uncontrolled gout.
Fight for Change: 2 ARP Members on Why Advocacy Is Important to Them
Two ARP members who currently serve on the ACR Government Affairs Committee discuss why & how they got involved in advocacy.
A Novel Study Compared the Effectiveness of Adalimumab with Tofacitinib in RA
Your patient with rheumatoid arthritis (RA) isn’t responding well enough to methotrexate, and you both agree it’s time to consider a biologic or targeted synthetic disease-modifying anti-rheumatic drug (DMARD). But which one should you choose? In a treat-to-target era, we’re fortunate to have a variety of RA therapies at our disposal. Clinical practice guidelines from…
RheumMadness 2023: The Results Are In
RheumMadness is an online tournament in which a bracket of teams, representing key learning concepts in rheumatology, compete against each other in a series of head-to-head matchups, much like basketball teams in the NCAA’s March Madness. The 2023 tournament theme was The All Star Season. Each team represented one all star article competing to be…
The Vital Role of the Physician Assistant
A team approach is necessary to provide comprehensive care in today’s complex healthcare settings. And nowhere is the need for a cadre of medical professionals more evident than within the practice of rheumatology, where complicated diagnoses and tailored treatments are the rule rather than the exception. Among the highly trained members of these healthcare teams…
Rheum After 5: Dr. Christopher Morris, Jeopardy! Contestant
The clock was ticking. Christopher Morris, MD, then an intern and resident in internal medicine at the University of Tennessee (UT) Medical Center, Knoxville, had just 30 seconds to think of the correct response. He already had the answer. His challenge was coming up with the question. Final Jeopardy In 1988, Dr. Morris, now a…
Late Summer 2023’s Awards, Appointments & Announcements in Rheumatology
PANLAR Names Eric L. Matteson, MD, a 2023 Master Throughout his career at the Mayo Clinic, Rochester, Minn., Eric L. Matteson, MD, currently professor of rheumatology, emeritus, actively engaged with his rheumatology colleagues in Latin America. He participated in conferences, worked on South American publications and brought rheumatology fellows to the Mayo Clinic for training….
Mixed Results for Rezpegaldesleukin in Patients with Active SLE
In a clinical trial, patients with active systemic lupus erythematosus (SLE) did not experience a reduction in disease activity with the addition of rezpegaldesleukin to their standard treatments. However, some patient populations did see improvements in their disease activity compared with the placebo-treated group.
Do NSAIDs Mask MRI Findings in Patients with Axial Spondyloarthritis?
Research suggests the use of non-steroidal anti-inflammatory drugs may mask the amount of sacroiliac joint inflammation found on MRI in patients with axial spondyloarthritis.